Intrommune Therapeutics Email Format

Biotechnology ResearchNew York, United States11-50 Employees

Intrommune Therapeutics is a biotechnology company based in New York, NY, focused on developing immunotherapy approaches for food allergies. Its primary aim is to create patient-friendly treatments that can be integrated into daily routines, with the first product targeting peanut allergy and a broader platform addressing other food allergies. The company emphasizes a long-term approach to immunotherapy, seeking safety, efficacy, and convenience for patients who live with these conditions.
Intrommune operates in the biotechnology research sector, pursuing an oral mucosal immunotherapy (OMIT) platform designed to address widespread food allergy challenges. The enterprise serves individuals affected by food allergies, including a substantial market in the United States, and positions itself as a clinical-stage player actively sharing data from early-stage trials. Recent activities include presenting exploratory efficacy data from a Phase 1 safety trial at a major allergy conference, reflecting ongoing clinical development and industry engagement.

Sign up for free to view info

Company overview Employee directory